External Link
You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.
Chronic pain is a complex phenomenon. Spanning five episodes, the podcast series offers diverse perspectives on chronic pain, featuring voices from patients, scientists, and healthcare experts to explore what lies beyond the pain.
Life’s small moments are incredibly precious. But pain snatches those moments away from billions of people and families every day. It puts restrictions on daily activities and disrupts sleep. It turns joyful events into occasions of stress and worry. And it forces many people to leave the workforce early. Pain is a disease that has a negative impact on individuals, communities and society as a whole. And the global burden of pain is increasingi.
One in every five people worldwide suffers from chronic painii – but 78 percent of those patients are not satisfied with their treatmentiii. It is estimated that up to 90 percent of adults with chronic pain experience a clinically significant degree of insomniaiv, while musculoskeletal pain contributes to 60 percent of permanent work incapacity in Europev. Pain is connected to conditions including anxiety and depressioniv that can make patients feel isolated. But they are not alone. Their stories matter.
Our people are united by a shared vision of a World Free of Pain. We believe patients deserve a life shaped by positivity and opportunity – not by suffering or frustration. During the last 50 years, our dedicated pain scientists have created several innovative treatments for people affected by pain. Now, Grünenthal is a global leader in pain research and management. But our work is not finished.
Every day, our experts passionately strive to develop next-generation medicines and make a positive impact on patients’ lives. Each individual at our company has their own unique motivations for choosing a career in fighting pain. And we join forces in our active search for life-changing innovations with the power to lift the burden for all patients around the globe.
Grünenthal pursues its vision of a World Free of Pain through extensive research and development. Experts from a variety of disciplines constantly search for new substances that could become active ingredients of innovative pain therapies – driven by the needs of millions of people who suffer from chronic pain around the world.
The scientists in Grünenthal’s state-of-the-art laboratories are constantly gaining a deeper understanding of the specific processes that cause pain in the body. Using our specialised expertise in this field, we seek to build on our company’s long tradition as a global leader in pain management – and bring to life our vision of a World Free of Pain.
To accelerate this push for progress, our researchers collaborate with partners worldwide to advance our pipeline of potential treatments. Our Boston Innovation Hub is a centre of excellence for pain research that connects Grünenthal with the scientific community within this innovation hotspot and beyond. This includes exploring additional modalities such as antibodies, peptide antagonists and genetic medicine approaches. Our R&D strategy focuses on identifying novel targets, engineering optimised clinical candidates, and rapidly progressing them to proof of concept and launch. At all times, we aim to find new therapies that address the unmet medical needs of patients.
